A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Sotatercept (Primary) ; Ruxolitinib
- Indications Anaemia; Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 22 Feb 2018 Planned End Date changed from 1 Feb 2020 to 1 Feb 2021.
- 05 Jan 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.
- 05 Jan 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History